Abstract
Invasive opportunistic fungal diseases (IFDs) are important causes of morbidity and mortality in paediatric patients with cancer and those who have had an allogeneic haemopoietic stem-cell transplantation (HSCT). Apart from differences in underlying disorders and comorbidities relative to those of adults, IFDs in infants, children, and adolescents are unique with respect to their epidemiology, the usefulness of diagnostic methods, the pharmacology and dosing of antifungal agents, and the absence of interventional phase 3 clinical trials for guidance of evidence-based decisions. To better define the state of knowledge on IFDs in paediatric patients with cancer and allogeneic HSCT and to improve IFD diagnosis, prevention, and management, the Fourth European Conference on Infections in Leukaemia (ECIL-4) in 2011 convened a group that reviewed the scientific literature on IFDs and graded the available quality of evidence according to the Infectious Diseases Society of America grading system. The final considerations and recommendations of the group are summarised in this manuscript.
| Original language | English |
|---|---|
| Pages (from-to) | E327-E340 |
| Number of pages | 14 |
| Journal | The Lancet Oncology |
| Volume | 15 |
| Issue number | 8 |
| Early online date | 29 Jun 2014 |
| DOIs | |
| Publication status | Published - Jul 2014 |
Bibliographical note
We are indebted to the other scientifi c faculty of the ECIL-4 meeting:Hamdi Akan, Murat Akova (Turkey); Dina Averbuch (Israel);
Rose-Mary Barnes (UK); Nicole Blijlevens (Netherlands); Thierry Calandra
(Switzerland); Catherine Cordonnier (France); Oliver Cornely (Germany);
Rafael de la Camara (Spai); Peter Donnelly (Netherlands); Lubos Drgona
(Slovakia); Hermann Einsele (Germany); Bertrand Gachot (France);
Corrado Girmenia (Italy); Ingeborg Gyssens (Netherlands); Werner Heinz
(Germany); Raoul Herbrecht (France); Hans Hirsch (Switzerland);
Petr Hubacek (Czech Republic); Chris Kibbler (UK); Galina Klyasova
(Russia); Michal Kouba (Czech Republic); Catherine Lagrou (Belgium);
Per Ljungman (Sweden); Johan Maertens (Belgium); Oscar Marchetti
(Switzerland); Rodrigo Martino (Spain); Georg Maschmeyer (Germany);
Tamas Masszi (Hungary); Suzanne Matthes-Martin (Austria);
Malgorzata Mikulska, Alessandra Micozzi (Italy); Bilal Mohty
(Switzerland); Patricia Munoz (Spain); David Nadal (Switzerland);
Christina Orasch (Switzerland); Zdenek Racil (Czech Republic);
Patricia Ribaud (France); Janos Sinko (Hungary); Alina Tanase (Hungary);
Mario Tumbarello (Italy); Paul Verweij (Netherlands); Claudio Viscoli
(Italy); Kate-Nora Ward (UK). We also thank the staff of KOBE, group GL
Events, Lyon, France, for the organisation of the meeting. The ECIL-4
meeting in Sept 9–10, 2011, was supported by unrestricted educational
grants of Astellas Pharma, Gilead Sciences, Merck & Co, and Pfi zer.
Astellas Pharma, Gilead Sciences, Merck & Co, and Pfi zer had no role in
the selection of experts and the design of the guideline; in the collection,
analysis, and interpretation of the data at any time including the
consensus conference; in the writing and editing of the guideline; or in
the decision to submit it for publication.
